This report provides a comprehensive analysis of the global anti-GFP nanobody market, examining its trajectory from 2025 through 2032. As essential tools for biological labeling and tracking, these single-domain antibodies are segmented by type, including monovalent and bispecific varieties, and by applications such as immunoprecipitation. The study evaluates key regional dynamics across the Americas, APAC, and Europe while profiling major industry players. Furthermore, it explores market drivers, competitive strategies, and emerging growth opportunities within the evolving biotechnology landscape.

Executive Overview

Market Summary

The global Anti-GFP Nanobody market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate over the forecast period.

Product Definition

Anti-GFP nanobody is a single-domain antibody specifically targeting green fluorescent protein (GFP), which is usually derived from camelids. Because GFP and its various derivatives are extensively utilized for labeling and tracking purposes within biological research, the anti-GFP nanobody has become an essential component of modern research tools.

Regional Market Analysis

Global Outlook

The global Anti-GFP Nanobody market is expected to undergo sustained expansion between 2025 and 2032.

United States

The United States market for Anti-GFP Nanobody is estimated to increase steadily from 2025 through 2032.

China

The China market for Anti-GFP Nanobody is estimated to experience growth from 2025 through 2032.

Europe

The Europe market for Anti-GFP Nanobody is estimated to see an increase in market value from 2025 through 2032.

Market Segmentation

By Type

• Monovalent Nanobodies
• Bivalent Nanobodies
• Bispecific Nanobodies
• Multivalent Nanobodies
• Fused Nanobodies

By Application

• Immunoprecipitation
• Chromatin Immunoprecipitation
• RNA Binding Protein Immunoprecipitation
• Other

By Geography

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

Competitive Landscape

Key Industry Players

The following companies have been profiled based on primary expert input and analysis of their market coverage, product portfolios, and market penetration:

• Sino Biological
• GenScript
• Proteintech Group
• Abiocenter
• MerryBio
• Pregene
• Cusabio
• Biocytogen
• Thermo Fisher Scientific
• QVQuality
• HUABIO
• Jackson ImmunoResearch

Market Dynamics

Global key players in the Anti-GFP Nanobody sector include Sino Biological, GenScript, Proteintech Group, Abiocenter, and MerryBio. In 2025, the two largest companies in the global market held a significant portion of the total revenue share.

About the Report

Report Scope and Methodology

LP Information, Inc. (LPI)'s newest research report, “Anti-GFP Nanobody Industry Forecast,” evaluates past sales and reviews total world Anti-GFP Nanobody sales in 2025. It provides a comprehensive analysis of projected sales for 2026 through 2032, broken down by region, market sector, and sub-sector, with detailed analysis provided in US$ millions.

This Insight Report offers a comprehensive analysis of the global Anti-GFP Nanobody landscape, highlighting key trends including:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

The report analyzes the strategies of leading global companies, focusing on their Anti-GFP Nanobody portfolios and capabilities, market entry strategies, market positions, and geographic footprints to understand their unique positions in an accelerating market.

Using a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, the study evaluates key market trends, drivers, and affecting factors to highlight emerging pockets of opportunity across type, application, geography, and market size.

Key Questions Addressed

• What is the 10-year outlook for the global Anti-GFP Nanobody market?
• What factors are driving Anti-GFP Nanobody market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Anti-GFP Nanobody market opportunities vary by end market size?
• How does Anti-GFP Nanobody break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Anti-GFP Nanobody Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Anti-GFP Nanobody by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Anti-GFP Nanobody by Country/Region, 2021, 2025 & 2032

  • 2.2 Anti-GFP Nanobody Segment by Type

    • 2.2.1 Monovalent Nanobodies

    • 2.2.2 Bivalent Nanobodies

    • 2.2.3 Bispecific Nanobodies

    • 2.2.4 Multivalent Nanobodies

    • 2.2.5 Fused Nanobodies

    • 2.2.6 Anti-GFP Nanobody Sales by Type

      • 2.2.6.1 Global Anti-GFP Nanobody Sales Market Share by Type (2021-2026)
      • 2.2.6.2 Global Anti-GFP Nanobody Revenue and Market Share by Type (2021-2026)
      • 2.2.6.3 Global Anti-GFP Nanobody Sale Price by Type (2021-2026)

  • 2.3 Anti-GFP Nanobody Segment by Application

    • 2.3.1 Immunoprecipitation

    • 2.3.2 Chromatin Immunoprecipitation

    • 2.3.3 RNA Binding Protein Immunoprecipitation

    • 2.3.4 Other

    • 2.3.5 Anti-GFP Nanobody Sales by Application

      • 2.3.5.1 Global Anti-GFP Nanobody Sale Market Share by Application (2021-2026)
      • 2.3.5.2 Global Anti-GFP Nanobody Revenue and Market Share by Application (2021-2026)
      • 2.3.5.3 Global Anti-GFP Nanobody Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Anti-GFP Nanobody Breakdown Data by Company

    • 3.1.1 Global Anti-GFP Nanobody Annual Sales by Company (2021-2026)

    • 3.1.2 Global Anti-GFP Nanobody Sales Market Share by Company (2021-2026)

  • 3.2 Global Anti-GFP Nanobody Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Anti-GFP Nanobody Revenue by Company (2021-2026)

    • 3.2.2 Global Anti-GFP Nanobody Revenue Market Share by Company (2021-2026)

  • 3.3 Global Anti-GFP Nanobody Sale Price by Company

  • 3.4 Key Manufacturers Anti-GFP Nanobody Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Anti-GFP Nanobody Product Location Distribution

    • 3.4.2 Players Anti-GFP Nanobody Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Anti-GFP Nanobody by Geographic Region

  • 4.1 World Historic Anti-GFP Nanobody Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Anti-GFP Nanobody Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Anti-GFP Nanobody Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Anti-GFP Nanobody Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Anti-GFP Nanobody Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Anti-GFP Nanobody Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Anti-GFP Nanobody Sales Growth

  • 4.4 APAC Anti-GFP Nanobody Sales Growth

  • 4.5 Europe Anti-GFP Nanobody Sales Growth

  • 4.6 Middle East & Africa Anti-GFP Nanobody Sales Growth

• 5 Americas

  • 5.1 Americas Anti-GFP Nanobody Sales by Country

    • 5.1.1 Americas Anti-GFP Nanobody Sales by Country (2021-2026)

    • 5.1.2 Americas Anti-GFP Nanobody Revenue by Country (2021-2026)

  • 5.2 Americas Anti-GFP Nanobody Sales by Type (2021-2026)

  • 5.3 Americas Anti-GFP Nanobody Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Anti-GFP Nanobody Sales by Region

    • 6.1.1 APAC Anti-GFP Nanobody Sales by Region (2021-2026)

    • 6.1.2 APAC Anti-GFP Nanobody Revenue by Region (2021-2026)

  • 6.2 APAC Anti-GFP Nanobody Sales by Type (2021-2026)

  • 6.3 APAC Anti-GFP Nanobody Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Anti-GFP Nanobody by Country

    • 7.1.1 Europe Anti-GFP Nanobody Sales by Country (2021-2026)

    • 7.1.2 Europe Anti-GFP Nanobody Revenue by Country (2021-2026)

  • 7.2 Europe Anti-GFP Nanobody Sales by Type (2021-2026)

  • 7.3 Europe Anti-GFP Nanobody Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Anti-GFP Nanobody by Country

    • 8.1.1 Middle East & Africa Anti-GFP Nanobody Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Anti-GFP Nanobody Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Anti-GFP Nanobody Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Anti-GFP Nanobody Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Anti-GFP Nanobody

  • 10.3 Manufacturing Process Analysis of Anti-GFP Nanobody

  • 10.4 Industry Chain Structure of Anti-GFP Nanobody

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Anti-GFP Nanobody Distributors

  • 11.3 Anti-GFP Nanobody Customer

• 12 World Forecast Review for Anti-GFP Nanobody by Geographic Region

  • 12.1 Global Anti-GFP Nanobody Market Size Forecast by Region

    • 12.1.1 Global Anti-GFP Nanobody Forecast by Region (2027-2032)

    • 12.1.2 Global Anti-GFP Nanobody Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Anti-GFP Nanobody Forecast by Type (2027-2032)

  • 12.7 Global Anti-GFP Nanobody Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Sino Biological

    • 13.1.1 Sino Biological Company Information

    • 13.1.2 Sino Biological Anti-GFP Nanobody Product Portfolios and Specifications

    • 13.1.3 Sino Biological Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Sino Biological Main Business Overview

    • 13.1.5 Sino Biological Latest Developments

  • 13.2 GenScript

    • 13.2.1 GenScript Company Information

    • 13.2.2 GenScript Anti-GFP Nanobody Product Portfolios and Specifications

    • 13.2.3 GenScript Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 GenScript Main Business Overview

    • 13.2.5 GenScript Latest Developments

  • 13.3 Proteintech Group

    • 13.3.1 Proteintech Group Company Information

    • 13.3.2 Proteintech Group Anti-GFP Nanobody Product Portfolios and Specifications

    • 13.3.3 Proteintech Group Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 Proteintech Group Main Business Overview

    • 13.3.5 Proteintech Group Latest Developments

  • 13.4 Abiocenter

    • 13.4.1 Abiocenter Company Information

    • 13.4.2 Abiocenter Anti-GFP Nanobody Product Portfolios and Specifications

    • 13.4.3 Abiocenter Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 Abiocenter Main Business Overview

    • 13.4.5 Abiocenter Latest Developments

  • 13.5 MerryBio

    • 13.5.1 MerryBio Company Information

    • 13.5.2 MerryBio Anti-GFP Nanobody Product Portfolios and Specifications

    • 13.5.3 MerryBio Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.5.4 MerryBio Main Business Overview

    • 13.5.5 MerryBio Latest Developments

  • 13.6 Pregene

    • 13.6.1 Pregene Company Information

    • 13.6.2 Pregene Anti-GFP Nanobody Product Portfolios and Specifications

    • 13.6.3 Pregene Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.6.4 Pregene Main Business Overview

    • 13.6.5 Pregene Latest Developments

  • 13.7 Cusabio

    • 13.7.1 Cusabio Company Information

    • 13.7.2 Cusabio Anti-GFP Nanobody Product Portfolios and Specifications

    • 13.7.3 Cusabio Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.7.4 Cusabio Main Business Overview

    • 13.7.5 Cusabio Latest Developments

  • 13.8 Biocytogen

    • 13.8.1 Biocytogen Company Information

    • 13.8.2 Biocytogen Anti-GFP Nanobody Product Portfolios and Specifications

    • 13.8.3 Biocytogen Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.8.4 Biocytogen Main Business Overview

    • 13.8.5 Biocytogen Latest Developments

  • 13.9 Thermo Fisher Scientific

    • 13.9.1 Thermo Fisher Scientific Company Information

    • 13.9.2 Thermo Fisher Scientific Anti-GFP Nanobody Product Portfolios and Specifications

    • 13.9.3 Thermo Fisher Scientific Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.9.4 Thermo Fisher Scientific Main Business Overview

    • 13.9.5 Thermo Fisher Scientific Latest Developments

  • 13.10 QVQuality

    • 13.10.1 QVQuality Company Information

    • 13.10.2 QVQuality Anti-GFP Nanobody Product Portfolios and Specifications

    • 13.10.3 QVQuality Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.10.4 QVQuality Main Business Overview

    • 13.10.5 QVQuality Latest Developments

  • 13.11 HUABIO

    • 13.11.1 HUABIO Company Information

    • 13.11.2 HUABIO Anti-GFP Nanobody Product Portfolios and Specifications

    • 13.11.3 HUABIO Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.11.4 HUABIO Main Business Overview

    • 13.11.5 HUABIO Latest Developments

  • 13.12 Jackson ImmunoResearch

    • 13.12.1 Jackson ImmunoResearch Company Information

    • 13.12.2 Jackson ImmunoResearch Anti-GFP Nanobody Product Portfolios and Specifications

    • 13.12.3 Jackson ImmunoResearch Anti-GFP Nanobody Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.12.4 Jackson ImmunoResearch Main Business Overview

    • 13.12.5 Jackson ImmunoResearch Latest Developments

• 14 Research Findings and Conclusion